PDF factsheet
      Z

HR-slowing agents in stable angina for patients with left ventricular dysfunction, clinical trials results

ivabradine 15mg versus placebo
BEAUTIFUL, 2008
NCT00143507
ivabradine target dose of 7ยท5 mg twice a day
versus
placebo
patients with coronary artery disease and left-ventricular systolic dysfunction (LVEF <=40%) double blind
Follow-up duration: 19 months (range 16-24)
33 countries

  Options


in first

in second

  Filter